Clinical considerations

Patients with CML are typically an older population who can be at risk for other health issues2,3
The incidence of CML increases with age2
The risk of CML increases with age with almost half of cases diagnosed in people 65 and older2
The most common comorbid conditions in patients diagnosed with CML are4,a:
Diabetes mellitus
Nonactive cancer
Chronic pulmonary disease
Moderate to severe renal insufficiency
Myocardial infarction
Cerebrovascular disease
Congestive heart failure
Peripheral vascular disease
aBosutinib not included in study cited.
In the general population, cardiovascular disease is common among older adults5
Ph+=Philadelphia chromosome–positive.
References
1.
BOSULIF Prescribing Information. New York, NY: Pfizer Inc.
2.
American Cancer Society. About Chronic Myeloid Leukemia. Cancer.org website. https://www.cancer.org/content/dam/CRC/PDF/Public/8684.00.pdf. Accessed August 20, 2018.
3.
Gugliotta G, Castagnetti F, Fogli M, Cavo M, Baccarani M, Rosti G. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Exp Rev Hematol. 2013;6(5):563-574.
4.
Saußele S, Krauß M-P, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126(1):42-49.
5.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146-e603. doi.org/10.1161/CIR.0000000000000485